标题
FN14 expression correlates with MET in NSCLC and promotes MET-driven cell invasion
作者
关键词
Non-small cell lung cancer, MET, FN14, Metastasis
出版物
CLINICAL & EXPERIMENTAL METASTASIS
Volume 31, Issue 6, Pages 613-623
出版商
Springer Nature
发表日期
2014-04-07
DOI
10.1007/s10585-014-9653-6
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Co-overexpression of Met and Hepatocyte Growth Factor Promotes Systemic Metastasis in NCI-H460 Non-Small Cell Lung Carcinoma Cells
- (2015) Roya Navab et al. NEOPLASIA
- The Src Homology 3 Domain-containing Guanine Nucleotide Exchange Factor Is Overexpressed in High-grade Gliomas and Promotes Tumor Necrosis Factor-like Weak Inducer of Apoptosis-Fibroblast Growth Factor-inducible 14-induced Cell Migration and Invasion via Tumor Necrosis Factor Receptor-associated Factor 2
- (2013) Shannon P. Fortin Ensign et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Elevated Expression of Fn14 in Non-Small Cell Lung Cancer Correlates with Activated EGFR and Promotes Tumor Cell Migration and Invasion
- (2012) Timothy G. Whitsett et al. AMERICAN JOURNAL OF PATHOLOGY
- SnapShot: Non-Small Cell Lung Cancer
- (2012) Rebecca S. Heist et al. CANCER CELL
- The TWEAK Receptor Fn14 Is a Therapeutic Target in Melanoma: Immunotoxins Targeting Fn14 Receptor for Malignant Melanoma Treatment
- (2012) Hong Zhou et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response
- (2012) Zhao Chen et al. NATURE
- Expression of Endoplasmic Reticulum Stress Proteins Is a Candidate Marker of Brain Metastasis in both ErbB-2+ and ErbB-2− Primary Breast Tumors
- (2011) Rebeca Sanz-Pamplona et al. AMERICAN JOURNAL OF PATHOLOGY
- Global cancer statistics
- (2011) Ahmedin Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- c-MET/Phospho-MET Protein Expression and MET Gene Copy Number in Non-small Cell Lung Carcinomas
- (2011) Koji Tsuta et al. Journal of Thoracic Oncology
- Development and Characterization of a Potent Immunoconjugate Targeting the Fn14 Receptor on Solid Tumor Cells
- (2011) H. Zhou et al. MOLECULAR CANCER THERAPEUTICS
- Met Activation in Non-Small Cell Lung Cancer Is Associated with de Novo Resistance to EGFR Inhibitors and the Development of Brain Metastasis
- (2010) Elisa Benedettini et al. AMERICAN JOURNAL OF PATHOLOGY
- Targeting the MET oncogene in cancer and metastases
- (2010) Giulia M Stella et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Nuclear localization of active HGF receptor Met in aggressive MDA-MB231 breast carcinoma cells
- (2009) E. Matteucci et al. CARCINOGENESIS
- Novel Therapeutic Inhibitors of the c-Met Signaling Pathway in Cancer
- (2009) J. P. Eder et al. CLINICAL CANCER RESEARCH
- Tumor Necrosis Factor-Like Weak Inducer of Apoptosis Stimulation of Glioma Cell Survival Is Dependent on Akt2 Function
- (2009) S. P. Fortin et al. MOLECULAR CANCER RESEARCH
- Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase
- (2009) Michel DuPage et al. Nature Protocols
- The Fibroblast Growth Factor-Inducible 14 Receptor Is Highly Expressed in HER2-Positive Breast Tumors and Regulates Breast Cancer Cell Invasive Capacity
- (2008) A. L. Willis et al. MOLECULAR CANCER RESEARCH
- A selective small molecule inhibitor of c-Met, PHA-665752, reverses lung premalignancy induced by mutant K-ras
- (2008) Y. Yang et al. MOLECULAR CANCER THERAPEUTICS
- The TWEAK–Fn14 cytokine–receptor axis: discovery, biology and therapeutic targeting
- (2008) Jeffrey A. Winkles NATURE REVIEWS DRUG DISCOVERY
- A Novel Multipurpose Monoclonal Antibody for Evaluating Human c-Met Expression in Preclinical and Clinical Settings
- (2008) Beatrice S. Knudsen et al. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now